|
|
 |
|
Viewing report
|
|
|
|
BioScrip Inc. Outlook Revised To Stable; 'B' Rating Affirmed
Standard & Poors
Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.
Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.
Abstract
U.S. pharmacy and infusion services provider BioScrip appears to be benefiting from the elimination of less profitable drugs and contracts from its infusion and pharmacy businesses. We are affirming our 'B' corporate credit on the company and all issue-related ratings. We are also revising our rating outlook to stable, reflecting our increasing confidence in BioScrip's ability to generate cash flow. NEW YORK (Standard & Poor's) May 4, 2011--Standard & Poor's Rating Services said today that it affirmed its 'B' corporate credit rating and all issue-level ratings on Elmsford, N.Y.-based pharmacy and infusion services provider BioScrip Inc. We revised the outlook to stable as the company's improved margins in the first quarter of 2011 increase our confidence in its strategy to...
Companies mentioned in this report are: BioScrip Inc.
Action: Affirmed
Action: Outlook: Stable
|
|
|
|
